Aberdeen life sciences firm NovaBiotics plans to test one of its drugs on Covid-19 patients with secondary lung infections. Hamish Burns writes in Insider that Nylexa ‘supercharges’ antibiotics to help them tackle difficult to treat and drug-resistant bacteria. Many of the lung infections in Covid-19 patients do not respond to antibiotics and more than half of the patients who died in Hubei province, the epicenter of the pandemic in China, succumbed to a secondary bacterial infection or sepsis.
NovaBiotics could begin making Nylexa for trials in May and in partnership with the NHS and subject to regulatory approvals, clinical studies could get under way soon after on patients hospitalized with Covid-19.
The active ingredient of Nylexa has proven to be safe and effective in clinical studies carried out across the UK, Italy and the US for bacterial lung infections associated with cystic fibrosis (CF). Nylexa could be repositioned as a Covid-19 therapy and tested on patients in the second half of 2020, ahead of any vaccine being available.